Genmab — November 2020
-
EGFR mutations are present in 10 to 15 percent of patients with NSCLC and occur in 40 to 50 percent of Asian patients who have NSCLC adenocarcinoma.[11],[12],[13] EGFR exon 20 insertion mutations identify a distinct subset of lung adenocarcinomas, accounting for at least nine percent of all EGFR mutations.[14] The five-year survival rate for patients with metastatic NSCLC is currently six percent.[15]
-
Genmab price target raised to $45 from $42 at H.C. Wainwright
-
-
the 2nd PhIII Amivantamab trial also starts recruiting. Still waiting for that milestone... https://clinicaltrials.gov/ct2/history/NCT04538664?A=3&B=4&C=merged#StudyPageTop
"5/11 09:29
" already had to laugh about that this morning and still laughing 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind